Cyclooxygenase selectivity of nonsteroidal anti-inflammatory drugs and risk of stroke

Archives of Internal Medicine

Volumn 168, Issue 11, 2008, Pages 1219-1224

  Haag, Mendel D M ^a   Bos, Michiel J ^a   Hofman, Albert ^a   Koudstaal, Peter J ^a   Breteler, Monique M B ^a   Stricker, Bruno H C ^a,b  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b Inspectorate for Health Care   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; AZAPROPAZONE; CARBASALATE CALCIUM; CELECOXIB; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; DICLOFENAC; ETORICOXIB; FLURBIPROFEN; IBUPROFEN; INDOMETACIN; KETOPROFEN; MELOXICAM; NABUMETONE; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; PIROXICAM; ROFECOXIB; SULINDAC; VALDECOXIB;

AGED; ARTICLE; CALCULATION; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; CHRONOTHERAPY; COHORT ANALYSIS; COMORBIDITY; COMPUTER ASSISTED TOMOGRAPHY; CONFIDENCE INTERVAL; DISEASE ASSOCIATION; DRUG SELECTIVITY; DRUG USE; FEMALE; FOLLOW UP; GROUPS BY AGE; HAZARD RATIO; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; NUCLEAR MAGNETIC RESONANCE IMAGING; PHARMACY; PRESCRIPTION; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; PROSPECTIVE STUDY; RISK ASSESSMENT; STATISTICAL MODEL; STROKE;

AGED; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CYCLOOXYGENASE INHIBITORS; FEMALE; HUMANS; INCIDENCE; MALE; NETHERLANDS; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; RISK FACTORS; STROKE;

EID: 45149095339     PISSN: 00039926     EISSN: 15383679     Source Type: Journal    
DOI: 10.1001/archinte.168.11.1219     Document Type: Article

References (36)

1. Bombardier C, Laine L, Reicin A, et al; VIGOR Study Group. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. N Engl J Med. 2000;343(21):1520-1528.
2. Bresalier RS, Sandler RS, Quan H, et al. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med. 2005;352(11):1092-1102.
3. Solomon SD, McMurray JJ, Pfeffer MA, et al. Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med. 2005;352(11):1071-1080.
4. ADAPT Research Group. Cardiovascular and cerebrovascular events in the randomized, controlled Alzheimer's Disease Anti-inflammatory Prevention Trial (ADAPT). PLoS Clin Trials. 2006;1(7):e33.
5. Lenzer J. FDA advisers warn: COX 2 inhibitors increase risk of heart attack and stroke. BMJ. 2005;330(7489):440.
6. Thrift AG, McNeil JJ, Forbes A, Donnan GA. Risk of primary intracerebral haemorrhage associated with aspirin and non-steroidal anti-inflammatory drugs: case-control study. BMJ. 1999;318(7186):759-764.
7. Bak S, Andersen M, Tsiropoulos I, et al. Risk of stroke associated with nonsteroidal anti-inflammatory drugs: a nested case-control study. Stroke. 2003;34(2):379-386.
8. Johnsen SP, Pedersen L, Friis S, et al. Nonaspirin nonsteroidal antiinflammatory drugs and risk of hospitalization for intracerebral hemorrhage: a population-based case-control study. Stroke. 2003;34(2):387-391.
9. Juvela S. Nonsteroidal anti-inflammatory drugs as risk factors for spontaneous intracerebral hemorrhage and aneurysmal subarachnoid hemorrhage [letter]. Stroke. 2003;34(6):e34-e36.
10. Johnsen SP, Pedersen L, Sørensen HT, et al. Nonsteroidal anti-inflammatory drugs as risk factors for spontaneous intracerebral hemorrhage and aneurysmal subarachnoid hemorrhage [reply]. Stroke. 2003;34(6):e34-e36.
11. Andersohn F, Schade R, Suissa S, Garbe E. Cyclooxygenase-2 selective nonsteroidal anti-inflammatory drugs and the risk of ischemic stroke: a nested case-control study. Stroke. 2006;37(7):1725-1730.
12. Catella-Lawson F, Crofford LJ. Cyclooxygenase inhibition and thrombogenicity. Am J Med. 2001;110(suppl 3A):28S-32S.
13. Antman EM, DeMets D, Loscalzo J. Cyclooxygenase inhibition and cardiovascular risk. Circulation. 2005;112(5):759-770.
14. Crofford LJ, Breyer MD, Strand CV, et al; International COX-2 Study Group. Cardiovascular effects of selective COX-2 inhibition: is there a class effect? J Rheumatol. 2006;33(7):1403-1408.
15. Mukherjee D, Nissen SE, Topol EJ. Risk of cardiovascular events associated with selective COX-2 inhibitors. JAMA. 2001;286(8):954-959.
16. Mamdani M, Rochon P, Juurlink DN, et al. Effect of selective cyclooxygenase 2 inhibitors and naproxen on short-term risk of acute myocardial infarction in the elderly. Arch Intern Med. 2003;163(4):481-486.
17. Graham DJ, Campen D, Hui R, et al. Risk of acute myocardial infarction and sudden cardiac death in patients treated with cyclo-oxygenase 2 selective and nonselective non-steroidal anti-inflammatory drugs: nested case-control study. Lancet. 2005;365(9458):475-481.
18. Hippisley-Cox J, Coupland C. Risk of myocardial infarction in patients taking cyclooxygenase-2 inhibitors or conventional non-steroidal anti-inflammatory drugs: population based nested case-control analysis. BMJ. 2005;330(7504):1366.
19. Hofman A, Breteler MM, van Duijn CM, et al. The Rotterdam Study: objectives and design update. Eur J Epidemiol. 2007;22(11):819-829.
20. Mitchell JA, Akarasereenont P, Thiemermann C, Flower RJ, Vane JR. Selectivity of nonsteroidal antiinflammatory drugs as inhibitors of constitutive and inducible cyclooxygenase. Proc Natl Acad Sci U S A. 1993;90(24):11693-11697.
21. Cryer B, Feldman M. Cyclooxygenase-1 and cyclooxygenase-2 selectivity of widely used nonsteroidal anti-inflammatory drugs. Am J Med. 1998;104(5):413-421.
22. Warner TD, Giuliano F, Vojnovic I, Bukasa A, Mitchell JA, Vane JR. Nonsteroid drug selectivities for cyclo-oxygenase-1 rather than cyclo-oxygenase-2 are associated with human gastrointestinal toxicity: a full in vitro analysis. Proc Natl Acad Sci U S A. 1999;96(13):7563-7568.
23. Giuliano F, Ferraz JG, Pereira R, de Nucci G, Warner TD. Cyclooxygenase selectivity of non-steroid anti-inflammatory drugs in humans: ex vivo evaluation. Eur J Pharmacol. 2001;426(1-2):95-103.
24. de Leval X, Delarge J, Dev P, et al. Evaluation of classical NSAIDs and COX-2 selective inhibitors on purified ovine enzymes and human whole blood. Prostaglandins Leukot Essent Fatty Acids. 2001;64(4-5):211-216.
25. Stichtenoth DO, Wagner B, Frolich JC. Effects of meloxicam and indomethacin on cyclooxygenase pathways in healthy volunteers. J Investig Med. 1997;45(2):44-49.
26. Van Hecken A, Schwartz JI, Depre M, et al. Comparative inhibitory activity of rofecoxib, meloxicam, diclofenac, ibuprofen, and naproxen on COX-2 versus COX-1 in healthy volunteers. J Clin Pharmacol. 2000;40(10):1109-1120.
27. Catella-Lawson F, Reilly MP, Kapoor SC, et al. Cyclooxygenase inhibitors and the antiplatelet effects of aspirin. N Engl J Med. 2001;345(25):1809-1817.
28. Konstantinopoulos PA, Lehmann DF. The cardiovascular toxicity of selective and nonselective cyclooxygenase inhibitors: comparisons, contrasts, and aspirin confounding. J Clin Pharmacol. 2005;45(7):742-750.
29. Bos MJ, Schipper CM, Koudstaal PJ, Witteman JC, Hofman A, Breteler MM. High serum C-reactive protein level is not an independent predictor for stroke: the Rotterdam Study. Circulation. 2006;114(15):1591-1598.
30. Ikram MA, Hollander M, Bos MJ, et al. Unrecognized myocardial infarction and the risk of stroke: the Rotterdam Study. Neurology. 2006;67(9):1635-1639.
31. Mosis G, Stijnen T, Castellsague J, et al. Channeling and prevalence of cardiovascular contraindications in users of cyclooxygenase 2 selective nonsteroidal antiinflammatory drugs. Arthritis Rheum. 2006;55(4):537-542.
32. Hinz B, Dormann H, Brune K. More pronounced inhibition of cyclooxygenase 2, increase in blood pressure, and reduction of heart rate by treatment with diclofenac compared with celecoxib and rofecoxib. Arthritis Rheum. 2006;54(1):282-291.
33. Shah AA, Thjodleifsson B, Murray FE, et al. Selective inhibition of COX-2 in humans is associated with less gastrointestinal injury: a comparison of nimesulide and naproxen. Gut. 2001;48(3):339-346.
34. Henry D, Lim LL, Garcia Rodriguez LA, et al. Variability in risk of gastrointestinal complications with individual non-steroidal anti-inflammatory drugs: results of a collaborative meta-analysis. BMJ. 1996;312(7046):1563-1566.
35. Krum H, Aw TJ, Liew D, Haas S. Blood pressure effects of COX-2 inhibitors. J Cardiovasc Pharmacol. 2006;47(suppl 1):S43-S48.
36. Catella-Lawson F, McAdam B, Morrison BW, et al. Effects of specific inhibition of cyclooxygenase-2 on sodium balance, hemodynamics, and vasoactive eicosanoids. J Pharmacol Exp Ther. 1999;289(2):735-741.